Stemline Therapeutics,Inc. (NASDAQ:STML) Files An 8-K Other EventsItem 8.01 Other Events.
On January 5, 2017, Stemline Therapeutics, Inc. announced an agreement with the U.S. Food and Drug Administration (FDA) on the registration pathway for SL-401 in first-line blastic plasmacytoid dendritic cell neoplasm (BPDCN).
A copy of the press release is being furnished as Exhibit 99.1 to this report.